Zacks Investment Research Upgrades Quotient Limited (NASDAQ:QTNT) to “Hold”

Quotient Limited (NASDAQ:QTNT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, August 9th.

According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

QTNT has been the subject of several other research reports. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Quotient Limited in a report on Tuesday, April 18th. ValuEngine upgraded shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th.

Shares of Quotient Limited (NASDAQ QTNT) traded down 8.44% during trading on Wednesday, hitting $3.58. 337,824 shares of the stock were exchanged. The stock has a 50-day moving average of $5.82 and a 200 day moving average of $6.59. Quotient Limited has a 12-month low of $3.52 and a 12-month high of $8.64. The stock’s market cap is $51.47 million.

Quotient Limited (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, hitting the consensus estimate of ($0.55). The business had revenue of $6.83 million during the quarter, compared to the consensus estimate of $5.70 million. Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. Equities analysts predict that Quotient Limited will post ($2.09) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Quotient Limited (NASDAQ:QTNT) to “Hold”” was published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/quotient-limited-nasdaqqtnt-stock-rating-upgraded-by-zacks-investment-research-updated.html.

In other Quotient Limited news, insider D J. Paul E. Cowan sold 54,460 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $4.06, for a total value of $221,107.60. Following the sale, the insider now directly owns 26,666 shares in the company, valued at $108,263.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider D J. Paul E. Cowan sold 45,032 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $6.57, for a total transaction of $295,860.24. Following the completion of the sale, the insider now owns 26,666 shares in the company, valued at $175,195.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 220,072 shares of company stock worth $1,282,778. 29.00% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund bought a new stake in Quotient Limited during the second quarter valued at about $101,000. Goldman Sachs Group Inc. bought a new stake in Quotient Limited during the second quarter valued at about $104,000. Nationwide Fund Advisors bought a new stake in Quotient Limited during the second quarter valued at about $111,000. Nicholas Hoffman & Company LLC. bought a new stake in Quotient Limited during the first quarter valued at about $150,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Quotient Limited during the second quarter valued at about $177,000. Hedge funds and other institutional investors own 38.97% of the company’s stock.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Get a free copy of the Zacks research report on Quotient Limited (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply